Pharmacokinetics of Oral Formulations of Gepotidacin (GSK2140944), a Triazaacenaphthylene Bacterial Type II Topoisomerase Inhibitor, in Healthy Adult and Adolescent Participants

Aline Barth, Mohammad Hossain, Darin B. Brimhall, Caroline R. Perry, Courtney A. Tiffany, Sherry Xu, Etienne F. Dumont

GlaxoSmithKline, Collegeville, Pennsylvania, USA
PPD, Las Vegas, Nevada, USA

ABSTRACT
Gepotidacin is a novel, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by a distinct mechanism of action (1, 2), which confers activity against most strains of Escherichia coli, Staphylococcus saprophyticus, and Neisseria gonorrhoeae, including those resistant to current antibiotics (3–7). Phase 2 clinical trials indicated that gepotidacin may be a viable treatment for urogenital gonorrhea, uncomplicated urinary tract infection (UTI), and acute bacterial skin and skin structure infections (8–10). Phase 3 confirmatory studies are currently in progress to support urogenital gonorrhea (ClinicalTrials.gov identifier NCT04010539) and uncomplicated UTI (ClinicalTrials.gov identifiers NCT04020341 and NCT04187144) indications.

Throughout phase 1 and 2 clinical development, the pharmacokinetics (PK) of gepotidacin have been well defined in healthy adult participants (8–15) and in participants

KEYWORDS gepotidacin, pharmacokinetics, relative bioavailability, adolescents, safety
with renal or hepatic impairment (16, 17). Gepotidacin formulations used in the PK evaluations included mesylate salt for an intravenous solution, capsules, tablets, and the free base for capsules and tablets. As clinical evaluation progressed, the mesylate salt oral tablet formulation was selected for potential commercialization. Here, we present data from 2 clinical studies that further evaluated gepotidacin PK and formulations. Results from a relative bioavailability study that compared 2 different free-base tablet formulations with a reference mesylate salt capsule formulation are presented. In addition, results are presented from a second clinical study with a mesylate salt tablet formulation. This study defined the PK of the final formulation for phase 3 evaluation, assessed the safety and systemic exposure of gepotidacin in a younger population to support the inclusion of adolescents ≥12 years of age in the phase 3 studies, and evaluated the optimum dosing time window for the second dose in the treatment of urogenital gonorrhea.

RESULTS

Relative bioavailability study. Twenty-six healthy adult participants were enrolled in this open-label study and received single oral doses of gepotidacin at 1,500 mg as two 750-mg roller-compacted (RC) free-base tablets, two 750-mg free-base high-shear wet granulation (HSWG) tablets, and three 500-mg mesylate salt reference capsules under fasted conditions in a randomized order separated by a washout of 3 days. All participants completed the study. The population consisted of 21 males and 5 females with a mean (range) body weight of 77.98 kg (54.6 to 115.0 kg) (Table 1).

(i) Pharmacokinetics. The 2 free-base RC and HSWG tablet formulations and the reference mesylate salt capsule formulation of gepotidacin were rapidly absorbed in plasma under fasted conditions, with similar time to reach the maximum observed concentration (T_{max}) and terminal elimination half-life (t_{1/2}) values (Fig. 1 and Table 2).
Intersubject variabilities across the 3 formulations were low for area under the concentration-time curve (AUC) from time zero to infinity (AUC$_{0\rightarrow\infty}$) (range, 23.0% to 25.7%) and moderate for maximum observed concentration (C$_{\text{max}}$) (range, 43.6% to 46.8%) values. The 90% confidence intervals (CIs) of the ratio of the free-base RC tablet to the mesylate salt capsule were within the 0.80-to-1.25 bioequivalence confidence bounds (18) for the AUC from time zero to the last quantifiable concentration (AUC$_{0\rightarrow t}$) (0.9792, 1.1062), AUC$_{0\rightarrow\infty}$ (0.9809, 1.1063), and C$_{\text{max}}$ (0.8440, 1.0888). Compared to the reference capsule, the free-base HSWG tablet met the 90% CI criteria for AUC$_{0\rightarrow t}$ (1.0479, 1.1838) and AUC$_{0\rightarrow\infty}$ (1.0459, 1.1797); however, the upper CI for C$_{\text{max}}$ (1.0113, 1.3047) did not meet the criteria (see Table S1 in the supplemental material).

For all 3 formulations evaluated, urine concentrations were measurable over the entire 48-h collection interval, with similar renal clearance (CLR) and percentage of the given dose excreted in urine (fe%) values (Fig. 2 and Table 3). As urine collection is representative of a time interval and not a single time point, the average concentrations at the midpoint of the collection intervals are used for plotting purposes in Fig. 2, while Table 3 details the specific time point from time zero to the time point indicated.

(ii) Safety and tolerability. Adverse events (AEs) were experienced by 50% of the participants (Table 4). The incidences of AEs were comparable when participants received HSWG tablets (35%) and mesylate salt capsules (31%) and were the lowest for the RC tablets (19%). Half of the participants experienced gastrointestinal AEs; the overall incidence was >10% for the AEs of diarrhea, abdominal pain, nausea, and flatulence.

Four of 26 participants (15%) experienced AEs of moderate severity; all other AEs reported were of mild severity, and no severe AEs were reported. One participant
### TABLE 2 Summary of oral gepotidacin plasma PK parameters in healthy participants across clinical studies

| PK parameter | Value for group | Relative bioavailability study (fasted) | Adult and adolescent study (administered with food) |
|--------------|-----------------|----------------------------------------|----------------------------------------------------|
| | | Adults, FB RC tablet, single dose, 1,500 mg (n = 26) | Adults, MS tablet, single dose, 1,500 mg (n = 14) | Adults, MS tablet, 2 doses 12 h apart |
| | | Adults, FB HSWG tablet, single dose, 1,500 mg (n = 26) | Adults, MS tablet, single dose, 1,500 mg (n = 13) | Adults, MS tablet, 2 doses 6 h apart |
| | | Adults, MS capsule, single dose, 1,500 mg (n = 26) | | Adolescents, MS tablet, 2 doses 6 h apart |
| C<sub>max</sub> (µg/mL) | 4.49 (43.6) | 4.66 (43.8) | 3.57 (38.1) | 11.0 (28.1) | 4.52 (29.5) | 8.42 (41.8) |
| T<sub>max</sub> (h) | 1.50 (0.50, 4.00) | 1.00 (0.50, 3.00) | 3.00 (1.50, 4.00) | 1.57 (1.00, 4.00) | 2.63 (0.50, 5.42) | 1.50 (1.00, 3.28) |
| AUC<sub>0</sub><sup>c</sup>–<sub>t</sub> (µg·h/mL) | 17.1 (23.4) | 18.3 (24.1) | 16.4 (26.2) | 91.2 (22.6) | 87.1 (26.3) |
| AUC<sub>0</sub><sup>c</sup>–<sub>1</sub> (µg·h/mL) | 17.5 (230) | 18.6 (24.0) | 16.7 (25.7) | 83.5 (22.7) | 82.4 (27.3) |
| AUC<sub>0</sub><sup>c</sup>–<sub>24</sub> (µg·h/mL) | — | — | — | 87.1 (26.3) | — |
| AUC<sub>0</sub><sup>c</sup>–<sub>48</sub> (µg·h/mL) | — | — | — | 87.1 (26.3) | — |
| AUC<sub>0</sub><sup>c</sup>–<sub>t</sub> (µg·h/mL) | — | — | — | 87.1 (26.3) | — |
| T<sub>lag</sub> (h) | 0.00 (0.00, 0.50) | 0.00 (0.00, 0.50) | 0.00 (0.00, 0.00) | — | — |
| CL/F (L/h) | — | — | — | 1.16 (12.7) | — |
| VZ/F (L) | — | — | — | 1.67 (25.9) | — |
| F<sub>rel</sub> | 1.05 (15.2) | 10.24 (12.1) | 10.29 (13.7) | — | — |
| R<sub>0</sub> C<sub>max</sub> | — | — | — | — | — |
| R<sub>0</sub> AUC<sub>0</sub><sup>c</sup>–<sub>t</sub> | — | — | — | — | — |

**Values are presented as geometric means (%CVb [percent between-participant geometric coefficients of variation]), except for T<sub>max</sub>, which is presented as medians (minima, maxima).**

- FB, free base; HSWG, high-shear wet granulation; MS, mesylate salt; n, number of participants with evaluable PK parameter data; RC, roller compacted.
- AUC<sub>0</sub><sup>c</sup>–<sub>t</sub>, area under the concentration-time curve from time zero to the time point indicated; CL/F, apparent clearance; C<sub>max</sub>, maximum observed concentration; F<sub>rel</sub>, relative bioavailability of drug; R<sub>0</sub>, accumulation ratio based on dose 2/dose 1; t<sub>lag</sub>, lag time before observation of drug concentrations; T<sub>max</sub>, time of occurrence of C<sub>max</sub>; V<sub>Z</sub>/F, apparent volume of distribution.

---

**a** The AUC<sub>0</sub><sup>c</sup>–<sub>t</sub>, C<sub>max</sub>, and T<sub>max</sub> PK parameters were estimated separately by dose when 2 doses were administered. Otherwise, parameters were estimated using the full profile; the t<sub>lag</sub> was based on plasma concentrations after the second dose.

**b** Dashes indicate where data were not determined.
reported a moderate AE of headache that was related to the HSWG tablets. Three participants reported moderate AEs of diarrhea, 1 related to the reference capsules and 2 related to the RC tablets. In 1 of these participants, gepotidacin administration was delayed in the next study period by approximately 2 h due to AEs of abdominal distension, flatulence, and diarrhea; however, the participant received the planned dose and completed the study without further delays or interruptions. There were no deaths, serious AEs, or AEs that led to discontinuation.

Clostridium difficile testing was performed for 2 participants; nucleic acid amplification test results and toxin A/B assay results were all negative. No clinically significant trends were observed in laboratory values, electrocardiogram (ECG) parameters, or vital sign measurements.

**Adult and adolescent study.** The adult and adolescent study was a double-blind, 2-part, sequential PK evaluation (Fig. 3) of the 750-mg gepotidacin mesylate salt commercial tablet formulation in adults and adolescents. Multiple tablets were administered to provide each required dose. All doses were administered with food.

In part 1, 14 healthy adult participants (≥ 18 to ≤ 64 years of age, inclusive) were randomly assigned to receive active oral doses of gepotidacin at 1,500 mg as a single dose, 3,000 mg given 12 h apart (6,000-mg total dose), and 3,000 mg given 6 h apart (6,000-mg total dose) in a fixed order separated by a washout of 3 days. Two adult participants were randomly assigned to receive matching placebo tablets under the same conditions. Of the 16 enrolled participants, 1 did not complete the study due to a family emergency. The adult safety population (n = 16) consisted of 9 males and 7 females.
### TABLE 3
Summary of oral gepotidacin urine PK parameters in healthy participants across clinical studies

| PK parameter | Value for group | | Value for group | | | Value for group | | | Value for group |
|--------------|----------------|--------|----------------|--------|--------|----------------|--------|--------|----------------|
| | **Adult relative bioavailability study (fasted)** | **Adults, MS tablet, 1,500-mg single dose (n = 26)** | **Adults, MS tablet, 2 × 3,000-mg doses 12 h apart (n = 13)** | **Adults, MS tablet, 2 × 3,000-mg doses 6 h apart (n = 13)** | **Adults, MS tablet, 2 × 3,000-mg doses 6 h apart (n = 12)** |
| | **FB RC tablet, 1,500-mg single dose (n = 26)** | **FB HSWG tablet, 1,500-mg single dose (n = 26)** | **MS capsule, 1,500-mg single dose (n = 26)** | **Adults, MS tablet, 1,500-mg single dose (n = 14)** | **Adolescents, MS tablet, 1,500-mg single dose (n = 13)** |
| AUC0–t (µg·h/mL) | | | | | | | | | | |
| | — | | | | | | | | | |
| AUC0–12 (µg·h/mL) | 1,948 (61.2) | 2,156 (74.8) | 1,904 (82.7) | — | — | | | | |
| AUC0–24 (µg·h/mL) | 2,464 (56.3) | 2,599 (69.0) | 2,373 (74.9) | 2,750 (69.4) | 3,660 (87.2) | 15,000 (62.4) | — | — | — |
| AUC0–48 (µg·h/mL) | 2,725 (54.4) | 2,768 (64.0) | 2,597 (69.5) | 2,980 (67.0) | 4,070 (84.7) | 16,400 (62.4) | — | — | — |
| 8–12-h concn (µg/mL) | — | — | — | 147 (153) | 155 (60.9) | — | — | — | — |
| CLR (L/h) | 16.7 (19.6) | 15.5 (22.3) | 16.8 (21.7) | 16.4 (19.6) | 15.1 (25.9) | 15.8 (13.0) | 14.3 (33.3) | 14.5 (26.4) | — |
| CLR/body wt (L/h/kg) | 0.218 (18.9) | 0.202 (25.3) | 0.218 (20.1) | — | — | — | — | — | — |
| fe% | 19.1 (22.2) | 19.0 (30.0) | 18.3 (28.6) | 21.5 (19.7) | 23.4 (25.5) | 24.0 (15.3) | 20.7 (31.7) | 27.9 (25.3) | — |
| Ae total (mg) | 287 (22.2) | 285 (30.0) | 275 (28.6) | 322 (19.7) | 352 (25.5) | 1,440 (15.3) | 1,240 (31.7) | 1,670 (25.3) | — |

*Values are presented as geometric means (%CVb [percent between-participant geometric coefficients of variation]), except for concentrations, which are presented as arithmetic means (%CV). The gepotidacin strength of all capsules and tablets administered was 750 mg; multiple capsules/tablets were administered to provide each required dose. FB, free base; HSWG, high-shear wet granulation; MS, mesylate salt; n, number of participants with evaluable PK parameter data; RC, roller compacted.

aAe total, total unchanged drug; CLR, area under the concentration-time curve from time zero to the timepoint indicated; fe%, percentage of drug excreted; t, 6- or 12-h dosing interval.

bThe minimum urine AUC0–12, AUC0–24, and AUC0–48 values in the relative bioavailability study were as follows: 807, 1,132, and 1,382 µg·h/mL, respectively, for the FB RC tablet; 700, 865, and 977 µg·h/mL, respectively, for the FB HSWG tablet; and 664, 995, and 1,158 µg·h/mL, respectively, for the MS capsule.

cThe minimum urine AUC0–24 and AUC0–48 values in the adult and adolescent study were as follows: 1,230 and 1,300 µg·h/mL, respectively, in adults and 618 and 659 µg·h/mL, respectively, in adolescents after a 1,500-mg single dose; 6,920 and 7,430 µg·h/mL in adults after two 3,000-mg doses 12 h apart; and 4,410 and 4,630 µg·h/mL, respectively, in adults and 5,840 and 6,240 µg·h/mL, respectively, in adolescents after two 3,000-mg doses 6 h apart.

dThe CLR was calculated as Ae total/AIDS0–t.

fe% and Ae total account for both doses of gepotidacin when 2 doses were administered.

dashes indicate where data were not determined.
with a mean (range) body weight of 79.08 kg (47.0 to 103.2 kg) and a mean (range) age of 45.6 years (27 to 64 years) (Table 1).

In part 2, 15 healthy adolescent participants (12 to 18 years of age, inclusive) were randomly assigned to receive active oral doses of gepotidacin at 1,500 mg as a single dose and 3,000 mg given 6 h apart (6,000-mg total dose) in a fixed order separated by a washout of 7 days. Three adolescent participants were randomly assigned to receive matching placebo tablets under the same conditions. The 6-h dose schedule for the adolescent participants was determined based on data review of adult safety and PK data from part 1. Of the 18 enrolled participants, 1 did not complete the study due to difficult venipunctures, 1 was able to swallow only the first tablet of the first dose and was withdrawn, and 1 was unable to swallow any tablets. Thus, 1 adolescent participant did not receive any study drug. The adolescent safety population (n = 17) consisted of 12 males and 5 females with a mean (range) body weight of 63.71 kg (40.5 to 88.1 kg) and a mean (range) age of 14.4 years (12 to 17 years) (Table 1). The mean body weight in adolescents was approximately 15 kg lower than that in adults.

(i) Adult pharmacokinetics. After a single dose of gepotidacin, plasma concentrations peaked at 3.00 h (Fig. 4). When 2 doses of gepotidacin were administered 12 or 6 h apart, 2 plasma concentration peaks were observed approximately 2.25 h and 1.5 h after the first and second doses, respectively. Maximum plasma concentrations were approximately 2.5-fold higher after each first dose of 3,000 mg than with the 1,500-mg single dose (Table 2). Mean AUC_{0-\infty} values, which were based on the full concentration-time profile, were approximately 4.4- to 4.6-fold higher after two 3,000-mg doses than with the 1,500-mg single dose. The accumulation ratios for C_{\text{max}} and AUC from time
zero to the 6- or 12-h dosing interval (AUC0–t) were approximately 40% higher when 2 doses were administered 6 h apart than when they were administered 12 h apart. Mean t1/2, apparent clearance (CL/F), and apparent volume of distribution (Vz/F) values were similar across the dose regimens.

Urine gepotidacin AUCs from time zero to 48 h postdose (AUC0–48) were 4- and 5.5-fold higher after two 3,000-mg doses 6 h apart and 12 h apart, respectively, than with the 1,500-mg single dose (Fig. 5 and Table 3). As urine collection is representative of a time interval and not a single time point, the average concentrations at the midpoint of the collection intervals are used for plotting purposes in Fig. 5, while Table 3 details the specific time point from time zero to the time point indicated. Renal clearance and fe% values were similar across the dose regimens.

(ii) Adolescent pharmacokinetics. Gepotidacin plasma concentrations peaked 3.00 h after single-dose administration. When 2 doses of gepotidacin were administered 6 h apart, plasma concentrations peaked 2.75 h after the first dose and 1.50 h after the second dose (Fig. 4). Maximum plasma concentrations were approximately 2.4-fold higher after the first 3,000-mg dose than with the 1,500-mg single dose, and the AUC0–t was approximately 5-fold higher after two 3,000-mg doses given 6 h apart than with the 1,500-mg single dose (Table 2). The accumulation ratios for AUC0–t and Cmax were 1.66 and 1.32, respectively, for the 6-h dosing interval. The t1/2 estimates and Vz/F were higher for the single dose than for 2 doses 6 h apart; however, CL/F estimates were similar for both dose regimens.

The gepotidacin urine AUC0–48 was 5.3-fold higher after two 3,000-mg doses 6 h apart than with the single 1,500-mg dose, with similar CLR and fe% values across the dose regimens (Fig. 5 and Table 3).

(iii) Pharmacokinetic comparisons. After the single 1,500-mg dose, mean Cmax values were 27% higher in adolescents than in adults, with similar Cmax ranges and comparable AUC0–1 values in both populations (Fig. 6 and Table 2). Likewise, after the first of two 3,000-mg doses was administered 6 h apart, the mean Cmax value was 29% higher in adolescents than in adults, with similar Cmax ranges in both populations. Overall, Cmax ranges and mean Cmax values were similar in adults and adolescents after the second 3,000-mg dose. The mean AUC from time zero to 24 h (AUC0–24) was approximately 35% higher in adolescents after the administration of 2 doses 6 h apart than in adults. The mean t1/2 values were similar in both populations after the single dose, with values of 11.5 h and 13 h in adults and adolescents, respectively. After
A  1,500 mg single dose; n = 14 adults (Part 1) and n = 13 adolescents (Part 2)

B  3,000 mg given 12 h apart; n = 13 adults (Part 1)

C  3,000 mg given 6 h apart; n = 13 adults (Part 1) and n = 12 adolescents (Part 2)

FIG 4 Arithmetic mean (SD) gepotidacin plasma concentration-time plots on a linear scale for the adult and adolescent study. Note that study part 1 included adults and study part 2 included adolescents. The lower limit of quantification is 0.01 μg/mL, represented by the dashed line.
FIG 5 Arithmetic mean (SD) gepotidacin urine concentration-time plots on a linear scale for the adult and adolescent study. Note that study part 1 included adults and study part 2 included adolescents. The lower limit of quantification is 1 µg/mL, represented by the dashed line. As urine collection is representative of a time interval and not a single time point, the average concentrations at the midpoint of the collection intervals are used for plotting purposes only.
2 doses 6 h apart, the mean \( t_{1/2} \) in adolescents was notably lower (6.98 h) than that in adults (12 h).

There were no differences observed in the total amount of gepotidacin excreted in urine between adults and adolescents after a single dose; however, after 2 doses 6 h apart, the total amount excreted was approximately 35% higher in adolescents than in adults (Table 3).

**(iv) Effect of emesis on pharmacokinetic data.** Seven participants (2 adults and 5 adolescents) experienced emesis when gepotidacin was administered as 2 doses given 6 or 12 h apart (Table S2), whereas no participants had emesis after the single dose of gepotidacin. Of these 7 participants, 1 adult experienced emesis after both dosing regimens of two 3,000-mg doses 6 and 12 h apart. The remaining 6 participants experienced emesis only after two 3,000-mg doses 6 h apart; the majority had emesis onset after the second dose. The time of onset of emesis ranged from approximately 1 to 4.5 h; there were no acute events of emesis that occurred less than 1 h after dosing (Table S2).
The data from these participants were not excluded from the analysis; however, the PK data were investigated for any impact of emesis. The plasma concentration-time profiles and the PK parameter values for these participants were generally similar or were within the range of values for participants without emesis, suggesting that emesis did not significantly impact gepotidacin exposure (Table S3 and Fig. S1).

(v) Pharmacokinetics and pharmacodynamics. The change from baseline in the corrected QT interval (QTc) for heart rate according to Fridericia (QTcF) data showed a slight positive trend of increasing as exposure to gepotidacin increased (Fig. 7). No individual adolescent or adult changes from baseline in QTcF were clinically meaningful, defined as a change from the baseline of 60 ms. No participants had a postdose QTcF value of 500 ms.

(vi) Safety and tolerability. A total of 69% of adult and 88% of adolescent participants experienced AEs during the study (Tables 5 and 6). After receiving placebo, 2 adolescent participants and no adults experienced AEs. In both populations, the incidence of AEs was lowest after the 1,500-mg single dose and higher when two 3,000-mg doses were administered 6 or 12 h apart. For the single dose, 7% of adults and 64% of adolescents experienced AEs. After 2 doses 6 h apart, 69% and 100% of adults and adolescents experienced AEs, respectively. For 2 doses 12 h apart, which were administered only to adults, 77% of participants experienced AEs. In both populations, gastrointestinal AEs were the most prevalent, affecting 56% of adults and 82% of adolescents, and primarily included diarrhea, nausea, abdominal discomfort, and vomiting. More gastrointestinal events occurred after the two 3,000-mg doses; the increase in AEs as the dose increased was observed in both adults and adolescents (Fig. 8). AEs of dizziness and headache.
were reported in 29% and 24% of adolescent participants; however, these AEs were not reported in adult participants.

Across both populations, AEs were of mild intensity, with the exception of 6 participants who experienced AEs of moderate severity, as follows: 1 adult and 4 adolescents experienced vomiting after receiving gepotidacin, and 1 adolescent experienced syncope after receiving placebo. There were no deaths, serious AEs, or AEs that led to discontinuation.

Based on the known safety profile for oral gepotidacin, AEs of special interest (AESIs) were specifically assessed in the analysis for cardiovascular and gastrointestinal events and events potentially related to acetylcholinesterase inhibition. A total of 3 participants across both populations had cardiovascular AESIs, all were mild, and 1 AE of supraventricular extrasystoles was considered related to gepotidacin by the investigator. Gastrointestinal AESIs were experienced by 9 adult participants and 14 adolescent participants; the most commonly reported AE was diarrhea in each population. Events compatible with acetylcholinesterase inhibition were observed in 9 adults and 13 adolescents and had a notable overlap with gastrointestinal events of nausea, diarrhea, abdominal discomfort, vomiting, and defecation urgency (Tables 5 and 6). Cumulative grades for acetylcholinesterase inhibition-related AESIs increased as the gepotidacin dose increased from a 1,500-mg single dose to two 3,000-mg doses 6 or 12 h apart (Fig. 9).

No clinically significant trends were observed in laboratory values, ECG parameters, or vital sign measurements in either population. No Holter abnormalities were identified throughout the study.

**DISCUSSION**

Throughout the clinical development program for gepotidacin, several different formulations have been evaluated. Initial clinical studies were conducted using gepotidacin mesylate salt capsule and free-base intravenous formulations. With progression to phase 2 evaluations and the identification of gepotidacin dose levels needed for efficacy, immediate-release film-coated tablets were developed to offer an acceptable size for patient convenience, to support a lower number of tablets per dose for patient compliance, and for manufacturing and scale-up feasibility purposes.

The first gepotidacin tablet formulation developed was a 750-mg-strength tablet using mesylate salt, which was compared in a relative bioavailability study to the

| System organ class, preferred term | 1,500-mg single dose (n = 14) | 2 × 3,000-mg doses 12 h apart (n = 13) | 2 × 3,000-mg doses 6 h apart (n = 13) | Placebo (n = 2) | Total (n = 16) |
|-----------------------------------|-------------------------------|--------------------------------------|-------------------------------------|----------------|---------------|
| Any adverse event                 | 1 (7)                         | 10 (77)                              | 9 (69)                              | 0              | 11 (69)       |
| Gastrointestinal disorders        |                               |                                      |                                     |                |
| Diarrhea                          | 1 (7)                         | 9 (69)                               | 8 (62)                              | 0              | 9 (56)        |
| Abdominal discomfort              | 0                             | 4 (31)                               | 4 (31)                              | 0              | 6 (38)        |
| Nausea                            | 0                             | 2 (15)                               | 3 (23)                              | 0              | 4 (25)        |
| Vomiting                          | 0                             | 1 (8)                                | 2 (15)                              | 0              | 2 (13)        |
| Defecation urgency                | 0                             | 1 (8)                                | 0                                   | 0              | 1 (6)         |
| Cardiac disorders                 | 0                             | 1 (8)                                | 0                                   | 0              | 1 (6)         |
| Arrhythmia                        | 0                             | 1 (8)                                | 0                                   | 0              | 1 (6)         |
| Investigations                    | 0                             | 0                                    | 1 (8)                               | 0              | 1 (6)         |
| Blood creatine phosphokinase      | 0                             | 0                                    | 1 (8)                               | 0              | 1 (6)         |
| increased                         |                               |                                      |                                     |                |
| Skin and subcutaneous disorders   | 0                             | 0                                    | 1 (8)                               | 0              | 1 (6)         |
| Dermatitis                        | 0                             | 0                                    | 1 (8)                               | 0              | 1 (6)         |

*The gepotidacin strength of the tablets administered was 750 mg; multiple capsules/tablets were administered to provide each required dose. Adverse event preferred terms presented in italics were associated with acetylcholinesterase inhibition in addition to the system organ class shown.*
reference 500-mg-strength capsule using mesylate salt at a total dose level of 1,500 mg under fed and fasted conditions (19). Both the tablet and reference capsule resulted in the rapid absorption of gepotidacin, with a median $T_{\text{max}}$ of 1.5 to 1.75 h under fasted conditions. The bioavailability of the tablet was comparable to that of the capsule under fasted conditions at a 1,500-mg dose, with geometric least-squares mean ratios of the test tablet to the reference capsule (90% CIs) of 1.079 (1.019, 1.144)

### TABLE 6 Summary of adverse events for oral gepotidacin mesylate salt tablets in healthy adolescent participants in the adult and adolescent study$	extsuperscript{a}$

| System organ class, preferred term | No. (%) of participants | 1,500-mg single dose ($n = 14$) | 2 × 3,000-mg doses 6 h apart ($n = 12$) | Placebo ($n = 3$) | Total ($n = 17$) |
|-----------------------------------|-------------------------|----------------------------------|--------------------------------------|-----------------|-----------------|
| Any adverse event                 | 9 (64)                  | 12 (100)                         | 2 (67)                               | 15 (88)         |
| Gastrointestinal disorders        | 6 (43)                  | 11 (92)                          | 2 (67)                               | 14 (82)         |
| Nausea                            | 0                      | 9 (75)                           | 1 (33)                               | 10 (59)         |
| Diarrhea                          | 3 (21)                  | 5 (42)                           | 1 (33)                               | 7 (41)          |
| Abdominal discomfort              | 2 (14)                  | 3 (25)                           | 1 (33)                               | 5 (29)          |
| Vomiting                          | 0                      | 5 (42)                           | 0                                    | 5 (29)          |
| Flatulence                        | 2 (14)                  | 2 (17)                           | 0                                    | 2 (12)          |
| Upper abdominal pain              | 1 (7)                   | 0                                | 0                                    | 1 (6)           |
| Nervous system disorders          | 2 (14)                  | 4 (33)                           | 1 (33)                               | 6 (35)          |
| Dizziness                         | 0                      | 4 (33)                           | 1 (33)                               | 5 (29)          |
| Headache                          | 2 (14)                  | 1 (8)                            | 1 (33)                               | 4 (24)          |
| Syncope                           | 0                      | 0                                | 1 (33)                               | 1 (6)           |
| Cardiac disorders                 | 1 (7)                   | 1 (8)                            | 0                                    | 2 (12)          |
| Supraventricular extrasystoles    | 0                      | 1 (8)                            | 0                                    | 1 (6)           |
| Tachycardia                       | 1 (7)                   | 0                                | 0                                    | 1 (6)           |
| General disorders and administration site conditions | 0 | 1 (8) | 0 | 1 (6) |
| Chest discomfort                  | 0                      | 1 (8)                            | 0                                    | 1 (6)           |
| Skin and subcutaneous disorders   | 1 (7)                   | 0                                | 0                                    | 1 (6)           |
| Dermatitis contact                | 1 (7)                   | 0                                | 0                                    | 1 (6)           |

$	extsuperscript{a}$The gepotidacin strength of the tablets administered was 750 mg; multiple capsules/tablets were administered to provide each required dose. Adverse event preferred terms presented in italics were associated with acetylcholinesterase inhibition in addition to the system organ class shown.

FIG 8 Plot of gastrointestinal adverse events of special interest in the adult and adolescent study. Note that data from both study part 1 and study part 2 are presented.
for $\text{AUC}_{0-\infty}$ and 1.036 (0.932, 1.152) for $C_{\text{max}}$. Additionally, food was shown to have a minimal effect on the rate and extent of absorption of the tablet in healthy adult participants.

The relative bioavailability data presented here evaluated 2 different tablet formulations that were manufactured with gepotidacin as a free base, rather than mesylate salt. The free-base RC and HSWG tablets were assessed against the reference mesylate salt capsule. Although this study was not designed to assess bioequivalence, the 90% CIs of the $\text{AUC}_{0-\infty}$ and $C_{\text{max}}$ parameter ratios for the RC tablet were within bioequivalence confidence bounds (18), and PK comparable to that of the reference capsule was also observed for the HSWG tablet, except for a slightly higher $C_{\text{max}}$. After oral 1,500-mg gepotidacin dose administration via RC or HSWG tablets or reference capsules, gepotidacin urine concentrations of $4.4 \, \text{mg/mL}$ were achieved and maintained over 24 h postdose, which is supportive of the uncomplicated UTI indication (9).

Pharmacokinetic comparison of data from the first study using the mesylate salt tablet (19) with data from the current relative bioavailability study of free-base RC and HSWG tablets showed similar plasma exposures. Comparing PK parameters across studies, after single-dose administration of gepotidacin at 1,500 mg under fasted conditions, mean $\text{AUC}_{0-\infty}$ values were 15.8, 17.5, and 18.6 $\mu$g · h/mL and mean $C_{\text{max}}$ values were 4.37, 4.49, and 5.35 $\mu$g/mL for the first mesylate salt tablet studied (19), the free-base RC tablet, and the free-base HSWG tablet, respectively. The mean $t_{1/2}$ values were 11.8 h for the mesylate salt tablet and 10.2 h for both free-base tablets. Given adequate AUC and $C_{\text{max}}$ exposures with the initial mesylate salt tablet formulation, and based on dissolution rates, a mesylate salt tablet formulation was further developed. A free-base 750-mg tablet formulation was evaluated in a phase 2a PK study in female participants with uncomplicated UTI (9), which demonstrated adequate systemic plasma and urine exposures, potential clinical and microbiological efficacy, and an acceptable safety-risk profile. This led to further formulation development and clinical evaluation of the 750-mg oral mesylate salt gepotidacin tablets in adults and adolescents as presented here.

The adult and adolescent study presented here was the first PK and safety clinical evaluation of the final, planned-to-be-commercial oral mesylate salt 750-mg tablet formulation for gepotidacin, not only in adults but also in an adolescent population. The data from the single 1,500-mg dose and the two 3,000-mg doses given 6 or 12 h apart...
supported the dose selections in the ongoing phase 3 studies in uncomplicated UTI (gepotidacin at 1,500 mg twice daily for 5 days [ClinicalTrials.gov identifiers NCT04020341 and NCT04187144]) and urogenital gonorrhea (gepotidacin at two 3,000-mg doses 10 to 12 h apart [ClinicalTrials.gov identifier NCT04010539]), respectively. Gepotidacin plasma AUC<sub>0–∞</sub> values were similar across the age populations for the 1,500-mg single-dose administration, although C<sub>max</sub> was found to be 27% higher in adolescents than in adults. With the administration of 2 doses, the plasma AUC<sub>0–24</sub> was approximately 35% higher in adolescents than in adults after both the first and second doses; however, C<sub>max</sub> was higher only after the first dose, by 29%, and was then found to be similar in both populations after the second dose. Thus, after the administration of 2 doses, plasma AUC<sub>0–24</sub> but not C<sub>max</sub> was elevated in adolescents. Assessments of these PK parameters are important; in a study of gepotidacin treatment of urogenital gonorrhea caused by *Neisseria gonorrhoeae*, AUC<sub>0–24</sub> exposure was a driver for gepotidacin efficacy as it impacted the ratio of the AUC of the free, unbound fraction of the drug (fAUC)/MIC (20); also note that the fAUC<sub>0–24</sub>/MIC ratio has been identified as the index best describing the efficacy of gepotidacin in the treatment of uncomplicated UTI caused by *Escherichia coli*. In addition, increased C<sub>max</sub> is related to a safety concern for QTc prolongation (15). A feasibility study to assess a modified-release formulation of gepotidacin to blunt the C<sub>max</sub> and the magnitude of the QTc effect is planned. Overall, based on the PK and safety data profiles, the inclusion of adolescent participants (≥12 years of age) in the phase 3 studies who weigh ≥40 kg was supported. Of interest, the adolescent participants weighed approximately 15 kg less than the adult participants; a weak correlation between plasma PK parameters and body weight was observed and showed the lower the body weight, the higher the gepotidacin exposure (see Fig. S2 in the supplemental material). In addition, the mean t<sub>1/2</sub> was approximately 5 h shorter in adolescents than in adults (6.98 h versus 12 h, respectively) when two 3,000-mg doses were administered 6 h apart (Table 2), but the terminal elimination profiles were similar, suggesting that the t<sub>1/2</sub> values would be similar between populations (Fig. S3). Thus, this may be an artifact of the PK sample collection time points, where the last sample was collected 48 h after the second dose in adolescents; however, in adults, there was an additional 60-h-postdose collection, which may have impacted the slope determination for the elimination rate.

Several adult and adolescent participants experienced emesis shortly after gepotidacin administration; thus, the impact of emesis on the PK data was investigated (Tables S2 and S3 and Fig. S1). Of the 6 participants with emesis after receiving 2 doses 6 h apart only, the majority had emesis onset across a range of approximately 1.5 to 4.5 h after the second dose. The individual T<sub>max</sub> values (Table S2) for these 6 participants do not suggest a consistent trend of occurrence before or after emesis. The T<sub>max</sub> range for participants with emesis ranged from 1 to 3 h, which was within the T<sub>max</sub> range for participants without emesis (0.50 to 5.42 h). No meaningful differences were observed for C<sub>max</sub> and AUC values across participants with or without emesis, suggesting that this was not a local gastric effect and that gepotidacin had reached a point of systemic absorption in the intestines before emesis onset. Overall, the occurrence of emesis did not impact the systemic plasma exposures in adults or adolescents.

From a safety perspective, in the relative bioavailability study of the free-base RC and HSWG tablets, there were no notable safety concerns observed. With the exception of 4 of 26 participants who experienced AEs of moderate severity that included diarrhea or headache, all other AEs were of mild severity. One participant with a moderate AE of diarrhea had a 2-h delay in gepotidacin administration in a subsequent study period; however, the participant received the full planned dose and completed the study.

In the commercial tablet formulation PK study, both adult and adolescent participants experienced AEsIs that were primarily associated with gastrointestinal and acetylcholinesterase inhibition events, which was expected based on the diversity and overlap of AEs associated with acetylcholinesterase inhibition. Such AEs cross over a range of body systems, including gastrointestinal, neurological, respiratory, and cardiovascular (see the supplemental material). These AEsIs increased in prevalence and severity as the
dose increased from a 1,500-mg single dose to two 3,000-mg doses given 6 or 12 h apart (6,000-mg total dose) (Fig. 8 and 9). The majority of AESIs were of mild severity, and none led to discontinuation from the study. Overall, similar AE profiles were observed between the dose regimens and age populations, even with higher PK exposures in adolescents. Although the incidence of AESIs was numerically higher in adolescents than in adults, the nature and intensity were similar. The reasons for this higher incidence are only speculative but could be related to anxiety associated with participating in a clinical trial. Based on the known AE profile for gepotidacin (3–10, 16, 17), gastrointestinal AESIs are commonly expected and were observed in both adults and adolescents in the present study, with an increase in such AESIs as the dose increased. It is anticipated that a proportion of gastrointestinal AESIs are associated with an off-target effect of gepotidacin, for example, acetylcholinesterase, which results in cholinergic effects either systemic or local to the gastrointestinal tract. However, further explanation would require additional research to explore the mechanism of gastrointestinal AESIs associated with gepotidacin.

In a previous thorough QTc evaluation, no QTcF effect of clinical importance was observed with higher exposures to gepotidacin, particularly at exposures of >14 μg/mL (15). Based on results from the present study in adults and adolescents (Fig. 7), there was no clinically relevant QTcF effect (i.e., no values of >500 ms and no increase from the baseline of >60 ms) associated with the systemic exposures of gepotidacin after total doses of 6,000 mg (i.e., 3,000 mg given 6 or 12 h apart) in either age population. Across the dose regimens and age groups, the cardiovascular safety-risk profiles were similar.

In the adult and adolescent study, the only gepotidacin formulation evaluated was the 750-mg mesylate salt commercial tablet formulation; thus, this limits direct PK and safety comparisons to the previous mesylate salt capsules or capsules and the free-base tablets.

Overall, similar systemic plasma and urine exposures were observed after the administration of various tablet and capsule formulations of gepotidacin, including several observations within the 0.80-to-1.25 confidence bounds for plasma PK parameters. The PK profile for the commercial gepotidacin mesylate salt tablet formulation has been fully characterized. The data support including adolescents with a body weight of at least 40 kg in the phase 3 evaluations using the same adult doses and regimens. In addition, the dosing interval in the phase 3 pivotal study for urogenital gonorrhea was determined to be 10 to 12 h between the first and second doses to support adequate systemic concentrations while also minimizing Cmax exposures. This increased time interval between doses may improve the gastrointestinal tolerability of the second dose by allowing an improvement or resolution of symptoms from the first dose while also minimizing Cmax-related adverse effects with the second dose. The urine exposures support the planned uncomplicated UTI indication from an MIC perspective (9). Data from both studies presented support an acceptable risk-safety profile for gepotidacin. The safety profile for the commercial gepotidacin tablet formulation in adult and adolescent participants was consistent with that observed in previous studies conducted in healthy participants, and no new safety concerns were identified. Ongoing phase 3 evaluations of the gepotidacin 750-mg mesylate salt tablet formulation will determine if this novel antibiotic will provide a much-needed oral therapeutic treatment option for uncomplicated UTI and urogenital gonorrhea.

MATERIALS AND METHODS

The relative bioavailability (ClinicalTrials.gov identifier NCT02853435) and adult and adolescent (ClinicalTrials.gov identifier NCT04079790) studies were conducted in male or female (nonpregnant, nonlactating) participants in good health as determined by the investigator based on medical history, clinical laboratory results, vital sign measurements, 12-lead ECG results, and physical examination findings. Participants were between 18 and 64 years of age, inclusive, in the relative bioavailability study and the first part of the adult and adolescent study. In the second part of the latter study, adolescent participants were between 12 and 17 years of age, inclusive. Both studies were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. The protocol and procedures were reviewed and approved by the IntegReview (Austin, TX, USA), Aspire (Santee, CA, USA), and Advarr (Columbia, MD, USA) institutional review boards. Written informed consent or assent was obtained from participants before any study procedures were performed.
Relative bioavailability study. (i) Study design. The relative bioavailability study was a 3-period crossover study to assess the relative bioavailability of a single 1,500-mg dose of gepotidacin in 2 free-base tablet formulations (two 750-mg RC and HSWG tablets) compared with the mesylate salt reference capsule formulation of gepotidacin (three 500-mg capsules). Each participant received all 3 treatments under fasted conditions according to an assigned treatment sequence based on a Latin-square design. There was a washout period of 3 days between doses. Participants were confined to the study site from period 1 through period 3 and returned to the study site for a follow-up visit 5 to 7 days after the last dose administration.

(ii) Pharmacokinetic assessments. Serial blood and urine samples were collected for PK analysis of gepotidacin concentrations up to approximately 48 h after each dose administration.

Blood samples were collected at predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, and 48 h post-dose. Urine was collected at predose and over the intervals of 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, and 36 to 48 h. The blood collection volume at each time point was approximately 3 mL.

Pharmacokinetic analysis. Noncompartmental PK analyses were performed using Phoenix WinNonlin version 6.4 for the relative bioavailability study and Phoenix WinNonlin version 8 (Certara USA, Inc., Princeton, NJ) for the adult and adolescent study. Actual sampling times were used in both analyses. All data were based on total gepotidacin concentrations as plasma protein binding of gepotidacin is low (33%) (GlaxoSmithKline, unpublished data). Concentration-time data are presented as arithmetic means, and PK parameter data are presented as geometric means, unless otherwise indicated.
(iv) Relative bioavailability analysis. In the relative bioavailability study, the log-transformed $\text{AUC}_{0-\infty}$, $\text{AUC}_{0-1}$, and $C_{\text{max}}$ values for gepotidacin were analyzed separately using a mixed-effects model with fixed-effect terms for sequence, period, and regimen and with participant within sequence as a random effect. Point estimates and 90% CIs for the differences of interest (RC tablets and HSWG tablets versus reference mesylate salt capsules) were constructed using the residual variance. The $T_{\text{max}}$ was analyzed nonparametrically using the Wilcoxon signed-rank test to compute the point estimate and 90% CI for the median difference for each comparison of interest. An analysis of variance was performed to obtain the geometric mean ratios between RC tablets and HSWG tablets versus reference mesylate salt capsules and 90% CIs for the ratios of $\text{AUC}_{0-\infty}$, $\text{AUC}_{0-1}$, and $C_{\text{max}}$.

(v) Pharmacokinetic and pharmacodynamic QTcF analysis. In the adult and adolescent study, QTcF evaluations and changes from baseline plots by gepotidacin concentrations were performed using SAS version 9.4 (SAS Institute, Inc., Cary, NC).

(vi) Safety analysis. Adverse events and changes from baseline values for clinical chemistry, hematology, vital signs, and ECG findings were analyzed using SAS version 9.3 for the relative bioavailability study and SAS version 9.4 (SAS Institute, Inc., Cary, NC) for the adult and adolescent study. For the adult and adolescent study, additional safety analyses were conducted to assess cardiovascular, gastrointestinal, and acetylcholinesterase inhibition-related AESIs. As acetylcholinesterase inhibition can be identified through multiple AEs, including an overlap with gastrointestinal events, 13 AE terms were identified in the analysis plan and via programming, and cumulative grades were determined (further analysis details are provided in the supplemental material).

(vii) Interim data review. In the adult and adolescent study, an interim data review was performed that consisted of reviewing data management listings and WinNonlin outputs. Preliminary plasma PK and safety results from adult participants in part 1 were reviewed by the sponsor and investigator before enrolling part 2 to determine the time interval between the 2 gepotidacin doses and to confirm PK sampling time points for adolescent participants.

Data availability. Anonymized individual participant data and study documents can be requested for further research from www.clinicalstudydatarequest.com.

SUPPLEMENTAL MATERIAL
Supplemental material is available online only.

SUPPLEMENTAL FILE 1, PDF file, 0.5 MB.

ACKNOWLEDGMENTS
We thank the study participants, clinical staff, and investigators for their participation. We also thank the PPD bioanalytical laboratory and the PK and biostatistics team for their analysis and study contributions, including Jodi Stahlman (PPD) and Rosie Robson (Ashfield MedComms, an Ashfield Health company) for editorial and writing assistance, which was supported by GlaxoSmithKline (Collegeville, PA, USA).

This study was supported by GlaxoSmithKline (Collegeville, PA, USA). This work was also supported in whole or in part with federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (HHSO100201300011C). Medical writing assistance was funded by GlaxoSmithKline.

A.B., C.R.P., and S.X. are employees of and own stock in GlaxoSmithKline. M.H., C.A.T., and E.F.D. are former employees of GlaxoSmithKline and hold company stock. Authors were not paid for their manuscript contributions.

D.B.B. was the principal investigator for the study. M.H., C.R.P., C.A.T., and E.F.D. contributed to the study concept or design. Only D.B.B. contributed to the acquisition of study data. All authors, with the exception of D.B.B., contributed to the data analysis or interpretation. All authors provided manuscript review and approval.

REFERENCES
1. Biedenbach DJ, Bouchillon SK, Hackel M, Miller LA, Scangarella-Oman NE, Jakielaszek C, Sahm DF. 2016. In vitro activity of gepotidacin, a novel triazaacenaphthylene bacterial topoisomerase inhibitor, against a broad spectrum of bacterial pathogens. Antimicrob Agents Chemother 60:1918–1923. https://doi.org/10.1128/AAC.02820-15.
2. Gibson EG, Bac B, Chan PF, Osheroff N. 2019. Mechanistic and structural basis for the actions of the antibacterial gepotidacin against Staphylococcus aureus gyrase. ACS Infect Dis 5:570–581. https://doi.org/10.1021/acsinfecdis.8b00315.
3. Bac BD, Chan PF, Eggleston DS, Forsbury A, Gentry DR, Gorcec F, Giordano J, Hann MM, Hennessy A, Hibbs M, Huang J, Jones E, Jones J, Brown KK, Lewis CJ, May EW, Saunders MR, Singh O, Spitzfaden CE, Shen C, Shillings A, Theobald AJ, Wohlkonig A, Pearson ND, Gwynn MN. 2010. Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 466:935–940. https://doi.org/10.1038/nature09197.
4. Scangarella-Oman N, Hossain M, Tiemeyer T, Jr, Perry CR, Tiffany C, Raychaudhuri A, Dumont E. 2019. Microbiological analysis from a phase II study evaluating gepotidacin (GSK2140944) in the treatment of uncomplicated urinary tract infections, poster 1482. Abstr IDWeek 2019, Washington, DC, 2 to 6 October 2019. https://www.eventscribe.com/2019/posters/IDWEEK/SplitViewer.asp?PID=NTIzNDE2NjEwODk.
5. Mushtaq S, Vickers A, Sadouki Z, Cole M, Fifer H, DoNascimento V, Day M, De Pinna E, Jenkins C, Godbole G, Woodford N. 2019. In vitro activities of gepotidacin, a novel triazaacenaphthylene topoisomerase IV and DNA gyrase inhibitor, against Gram-negative bacteria and Staphylococcus.
saprophyticus, poster P1849. Abstr ECCMID 2019, Amsterdam, The Nether-lands, 13 to 16 April 2019.

6. Jacobsson S, Golparian D, Scangarella-Oman N, Unemo M. 2018. In vitro ac-
tivity of the novel triazaacenaphthylene gepotidacin (GSK2140944) against
MDR Neisseria gonorrhoeae. J Antimicrob Chemother 73:2072–2077. https://
doi.org/10.1093/jac/dky162.

7. Farrell DJ, Sader HS, Rhomberg PR, Scangarella-Oman NE, Flamm RK. 2017.
In vitro activity of gepotidacin (GSK2140944) against Neisseria gon-
orrhoeae. Antimicrob Agents Chemother 61:e02047-16. https://doi.org/10
.1128/AAC.02047-16.

8. Taylor SN, Morris DH, Avery AK, Workowski KA, Batteiger BE, Tiffany CA,
Perry CR, Raychaudhuri A, Scangarella-Oman NE, Hossain M, Dumont EF.
2018. Gepotidacin for the treatment of uncomplicated urogenital gonor-
rhea: a phase 2, randomized, dose-ranging, single-oral dose evaluation.
Clin Infect Dis 67:504–512. https://doi.org/10.1093/cid/ciy145.

9. Overcash JS, Tiffany CA, Scangarella-Oman NE, Perry CR, Tao Y, Hossain M,
Barth A, Dumont EF. 2020. Phase 2a pharmacokinetic, safety, and explor-
atory efficacy evaluation of oral gepotidacin (GSK2140944) in female par-
ticipants with uncomplicated urinary tract infection (acute uncomplic-
cated cystitis). Antimicrob Agents Chemother 64:e00199-20. https://doi
.org/10.1128/AAC.00199-20.

10. O’Riordan W, Tiffany C, Scangarella-Oman N, Perry C, Hossain M, Ashton
T, Dumont E. 2017. Efficacy, safety, and tolerability of gepotidacin
(GSK2140944) in the treatment of patients with suspected or confirmed
Gram-positive acute bacterial skin and skin structure infections. Antimi-
crob Agents Chemother 61:e02095-16. https://doi.org/10.1128/AAC
02095-16.

11. Negash K, Andonian C, Felgate C, Chen C, Goljer I, Squillaci B, Nguyen D,
Pinhalla J, Lev M, Schubert E, Tiffany C, Hossain M, Ho M. 2016. The metab-
olism and disposition of GSK2140944 in healthy human subjects. Xenobi-
otaica 46:683–702. https://doi.org/10.3109/00498254.2015.1112933.

12. Tiffany CA, Hossain M, McDonald M, Patel A, Lerman S, Patel P, Widdowson
KL, Dumont EF. 2013. Safety and pharmacokinetics of single escalating oral
doses of GSK2140944, a novel bacterial topoisomerase inhibitor, abstr F-
1218. Abstr 53rd Intersci Conf Antimicrob Agents Chemother, Denver, CO,
10 to 13 October 2013.

13. Tiffany CA, Hossain M, McDonald M, Lerman S, Dumont EF. 2014. Safety
and pharmacokinetics of single escalating IV doses of GSK2140944, a novel
bacterial topoisomerase inhibitor, abstr F-277. Abstr 54th Intersci Conf
Antimicrob Agents Chemother, Washington, DC, 5 to 9 September 2014.

14. Tiffany CA, Hossain M, McDonald M, Lerman S, Dumont EF. 2014. Safety
and pharmacokinetics of repeat escalating IV doses of GSK2140944, a novel
bacterial topoisomerase inhibitor, abstr F-278. Abstr 54th Intersci Conf
Antimicrob Agents Chemother, Washington, DC, 5 to 9 September 2014.

15. Hossain M, Zhou M, Tiffany C, Dumont E, Darpo B. 2017. A phase I, ran-
domized, double-blinded, placebo- and moxi-floxacin-controlled, four-
period crossover study to evaluate the effect of gepotidacin on cardiac
conduction as assessed by 12-lead electrocardiogram in healthy volun-
teers. Antimicrob Agents Chemother 61:e02385-16. https://doi.org/10
.1128/AAC.02385-16.

16. Hands JT, Tao Y, Tiffany C, Perry CR, Dumont E, Hossain M. 2019. Pharma-
cokinetics of gepotidacin (GSK2140944) in subjects with hepatic impair-
ment. Open Forum Infect Dis 6(Suppl 2):S327. https://doi.org/10.1093/ofid/ofz360.799.

17. Hossain M, Tiffany C, Raychaudhuri A, Nguyen D, Tai G, Alcorn H, Jr,
Preston RA, Marbury T, Dumont E. 2020. Pharmacokinetics of gepotidacin
in renal impairment. Clin Pharmacol Drug Dev 9:560–572. https://doi.org/
10.1002/cpdd.807.

18. Food and Drug Administration, Center for Drug Evaluation and Research.
2001. Statistical approaches to establishing bioequivalence. Food and
Drug Administration, Rockville, MD. https://www.fda.gov/media/70958/
download. Accessed 19 August 2020.

19. Hossain M, Tiffany CA, McDonald M, Dumont EF. 2015. Bioavailability and
drug-drug interaction profile of GSK2140944, a novel bacterial topoisom-
erase inhibitor, poster A-028. Abstr 55th Intersci Conf Antimicrob Agents
Chemother, San Diego, CA, 17 to 21 September 2015.

20. Scangarella-Oman NE, Hossain M, Dixon PB, Ingraham K, Min S, Tiffany
CA, Perry CR, Raychaudhuri A, Dumont EF, Huang J, Hook EW, III, Miller
LA. 2018. Microbiological analysis from a phase 2 randomized study in
adults evaluating single oral doses of gepotidacin in the treatment of
uncomplicated urogenital gonorrhea caused by Neisseria gonorrhoeae.
Antimicrob Agents Chemother 62:e01221-18. https://doi.org/10.1128/
AAC.01221-18.